Imunon, Inc. (0HUZ.L)
USD 0.88
(-5.44%)
USD 0.88
(-5.44%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.69 Million USD | 37.35% |
| 2022 | -6.72 Million USD | 48.07% |
| 2021 | -12.95 Million USD | -18.08% |
| 2020 | -10.96 Million USD | -345.96% |
| 2019 | 4.45 Million USD | 213.29% |
| 2018 | -3.93 Million USD | 65.6% |
| 2017 | -11.44 Million USD | -17891.25% |
| 2016 | -63.6 Thousand USD | 97.76% |
| 2015 | -2.84 Million USD | 4.64% |
| 2014 | -2.97 Million USD | -321.08% |
| 2013 | -707.61 Thousand USD | 95.28% |
| 2012 | -14.99 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -838.3 Thousand USD | 80.11% |
| 2024 Q2 | -3.91 Million USD | -367.3% |
| 2023 FY | -4.21 Million USD | 37.35% |
| 2023 Q3 | -11.14 Million USD | -112.31% |
| 2023 Q2 | -5.25 Million USD | -3.38% |
| 2023 Q1 | -5.07 Million USD | 24.49% |
| 2023 Q4 | -4.21 Million USD | 62.2% |
| 2022 Q3 | -20.57 Million USD | -1.43% |
| 2022 Q1 | -21.81 Million USD | -68.42% |
| 2022 Q4 | -6.72 Million USD | 67.31% |
| 2022 FY | -6.72 Million USD | 48.07% |
| 2022 Q2 | -20.28 Million USD | 7.01% |
| 2021 Q1 | -31.63 Million USD | -177.4% |
| 2021 FY | -12.95 Million USD | -18.08% |
| 2021 Q2 | -19.74 Million USD | 37.59% |
| 2021 Q3 | -18.93 Million USD | 4.1% |
| 2021 Q4 | -12.95 Million USD | 31.59% |
| 2020 Q2 | -11.72 Million USD | -325.73% |
| 2020 Q4 | -11.4 Million USD | 8.58% |
| 2020 FY | -10.96 Million USD | -345.96% |
| 2020 Q1 | 5.19 Million USD | 27.54% |
| 2020 Q3 | -12.47 Million USD | -6.39% |
| 2019 Q2 | 4.93 Million USD | -33.06% |
| 2019 FY | 4.45 Million USD | 213.29% |
| 2019 Q4 | 4.07 Million USD | 67.66% |
| 2019 Q3 | 2.42 Million USD | -50.82% |
| 2019 Q1 | 7.37 Million USD | 287.42% |
| 2018 Q2 | -3.53 Million USD | -54.53% |
| 2018 Q1 | -2.28 Million USD | 80.03% |
| 2018 FY | -3.93 Million USD | 65.6% |
| 2018 Q4 | -3.93 Million USD | -166.18% |
| 2018 Q3 | 5.94 Million USD | 268.43% |
| 2017 Q2 | -3.62 Million USD | -21.06% |
| 2017 FY | -11.44 Million USD | -17891.25% |
| 2017 Q4 | -11.44 Million USD | -326.22% |
| 2017 Q3 | -2.68 Million USD | 26.01% |
| 2017 Q1 | -2.99 Million USD | -4612.75% |
| 2016 Q3 | -591.11 Thousand USD | 92.35% |
| 2016 Q2 | -7.72 Million USD | 12.07% |
| 2016 Q1 | -8.79 Million USD | -209.36% |
| 2016 FY | -63.6 Thousand USD | 97.76% |
| 2016 Q4 | -63.6 Thousand USD | 89.24% |
| 2015 Q4 | -2.84 Million USD | -1019.89% |
| 2015 Q3 | -253.72 Thousand USD | 93.32% |
| 2015 Q2 | -3.79 Million USD | -385.72% |
| 2015 Q1 | 1.32 Million USD | 144.63% |
| 2015 FY | -2.84 Million USD | 4.64% |
| 2014 Q4 | -2.97 Million USD | -159.23% |
| 2014 Q3 | 5.03 Million USD | 10514.18% |
| 2014 Q2 | 47.39 Thousand USD | -87.96% |
| 2014 Q1 | 393.73 Thousand USD | 155.64% |
| 2014 FY | -2.97 Million USD | -321.08% |
| 2013 Q1 | -15.36 Million USD | -2.5% |
| 2013 FY | -707.61 Thousand USD | 95.28% |
| 2013 Q3 | -8.9 Million USD | -579.65% |
| 2013 Q2 | -1.31 Million USD | 91.47% |
| 2013 Q4 | -707.61 Thousand USD | 92.05% |
| 2012 Q4 | -14.99 Million USD | 0.0% |
| 2012 FY | -14.99 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 95.435% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 84.946% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 102.373% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 114.738% |
| bluebird bio, Inc. | 108.57 Million USD | 104.328% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 47.879% |
| Editas Medicine, Inc. | -87.11 Million USD | 94.606% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.037% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 100.224% |
| Myriad Genetics, Inc. | 88.1 Million USD | 105.334% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 102.65% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 85.984% |
| Verastem, Inc. | -37.27 Million USD | 87.394% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.057% |
| Waters Corporation | 1.96 Billion USD | 100.24% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.018% |
| Biogen Inc. | 6.28 Billion USD | 100.075% |
| Nektar Therapeutics | 210.24 Million USD | 102.235% |
| Perrigo Company plc | 3.32 Billion USD | 100.141% |
| Dynavax Technologies Corporation | 106.63 Million USD | 104.407% |
| Illumina, Inc. | 1.21 Billion USD | 100.387% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 167.44% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 95.874% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 103.239% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 165.386% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 101.241% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 33.813% |
| Evolus, Inc. | 63.7 Million USD | 107.376% |
| Adicet Bio, Inc. | -142 Million USD | 96.691% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 87.232% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 82.66% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.024% |
| FibroGen, Inc. | 56.76 Million USD | 108.278% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 100.41% |
| OPKO Health, Inc. | 230.68 Million USD | 102.037% |
| Homology Medicines, Inc. | 18.43 Million USD | 125.488% |
| Geron Corporation | 14.76 Million USD | 131.836% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 100.296% |
| Exelixis, Inc. | -73.05 Million USD | 93.567% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 91.339% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 96.888% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 95.782% |
| Zoetis Inc. | 4.76 Billion USD | 100.099% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 97.648% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 53.339% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.951% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 67.751% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.446% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 100.485% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 96.529% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.34% |
| Blueprint Medicines Corporation | 702.83 Million USD | 100.669% |
| Insmed Incorporated | 721.62 Million USD | 100.651% |
| TG Therapeutics, Inc. | 17.86 Million USD | 126.309% |
| Incyte Corporation | -3.17 Billion USD | 99.852% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 100.614% |